15 October 2025
Novo Nordisk Acquires Rights to Omeros' MASP-3 Inhibitor Zaltenibart
Zaltenibart, a MASP-3 inhibitor, targets rare blood and kidney disorders. Omeros receives up to $2.1 billion, plus royalties. Novo Nordisk plans global phase 3 trials.